FDA approves Truvada(Gilead Sciences) for HIV Prevention - 17-Jul-2012

The FDA has approved Truvada (emtricitabine/tenofovir disoproxil fumarate) from Gilead Sciences, the first drug approved to reduce the risk of HIV infection in uninfected individuals who are at high risk of HIV infection and who may engage in sexual activity with HIV-infected partners. Truvada, taken daily, is to be used for pre-exposure prophylaxis (PrEP) in combination with safer sex practices to reduce the risk of sexually-acquired HIV infection in adults at high risk.

Related News

Related HIV/AIDS Information

Back to top

Latest News

10 May 2015
25 May 2013
25 May 2013